Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ondansetron. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A known ✓ | P46098 | 2/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.98 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.98 |
| ▸ | HTR2B | P41595 | 2/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.98 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.98 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.98 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.98 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.98 |
| ▸ | HTR3B | O95264 | 1/20 | 0.98 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.98 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.98 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.98 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.98 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.98 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 0.98 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.98 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.98 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ondansetron SCHEMBL6186944 | 1.00 | CYP3A4 (0.98) | CYP3A4KCNH2CYP1A2HTR2BHTR3A | |
| (R)-Ondansetron SCHEMBL5123895 | 1.00 | CYP3A4 (0.98) | CYP3A4KCNH2CYP1A2HTR2BHTR3A | |
| (R)-Ondansetron SCHEMBL6186951 | 1.00 | CYP3A4 (0.98) | CYP3A4KCNH2CYP1A2HTR2BHTR3A | |
| (R)-Ondansetron SCHEMBL157565 | 0.99 | CYP3A4 (0.96) | CYP3A4KCNH2CYP1A2HTR2BHTR3A | |
| Ondansetron SCHEMBL8153849 | 0.99 | CYP3A4 (0.96) | CYP3A4KCNH2CYP1A2HTR2BHTR3A | |
| Ondansetron SCHEMBL25018 | 0.99 | CYP3A4 (0.96) | CYP3A4KCNH2CYP1A2HTR2BHTR3A | |
| Ondansetron SCHEMBL29387592 | 0.99 | CYP3A4 (0.96) | CYP3A4KCNH2CYP1A2HTR2BHTR3A | |
| Ondansetron SCHEMBL1172987 | 0.99 | CYP3A4 (0.96) | CYP3A4KCNH2CYP1A2HTR2BHTR3A | |
| Ondansetron SCHEMBL7217409 | 0.99 | CYP3A4 (0.96) | CYP3A4KCNH2CYP1A2HTR2BHTR3A | |
| (R)-Ondansetron SCHEMBL7217414 | 0.99 | CYP3A4 (0.96) | CYP3A4KCNH2CYP1A2HTR2BHTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7390503-B1 | Ondansetron orally disintegrating tablets | BARR LABORATORIES, INC. (US) | 2008-06-24 | — | — | US | disclosed |
| US-7288660-B2 | Process for preparing ondansetron hydrochloride dihydrate having a defined particle size | TARO PHARMACEUTICAL INDUSTRIES LIMITED (IL) | 2007-10-30 | — | — | US | disclosed |
| US-20050261351-A1 | Process for preparing ondansetron hydrochloride dihydrate having a defined particle size | TARO PHARMACEUTICALS INDUSTRIES LIMITED (IL) | 2005-11-24 | — | — | US | disclosed |
| CN-1498216-A | Noval crystal and solvate forms of ondansetron hydrochloride and process for their preparation | ������ҩ��ҵ����˾ | 2004-05-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261351-A1 | Process for preparing ondansetron hydrochloride dihydrate having a defined particle size | NPSR1, SI, HTR5A | HTR3A 8/4885CYP3A4 15/4885KCNH2 1828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.